US EditionEma Reviews a Drug Against 'Mpox' Having Been Questioned for Its Efficacy
Summary by Noticias De Navarra
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The European Medicines Agency (EMA) has initiated a review of 'Tecovirimat SIGA' (tecovirimat) of the pharmaceutical company SIGA, following the publication of preliminary data from recent clinical trials that question its efficacy in the treatment of smallpox monkey (mpox).
·Pamplona, Spain
Read Full Article
The European Medicines Agency (EMA) has initiated a review of 'Tecovirimat SIGA' (tecovirimat) of the pharmaceutical company SIGA, following the publication of preliminary data from recent clinical trials that question its efficacy in the treatment of smallpox monkey (mpox).
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
